Currently, there are 96.90M common shares owned by the public and among those 91.14M shares have been available to trade.
The company’s stock has a 5-day price change of -26.98% and -40.92% over the past three months. SRPT shares are trading -39.52% year to date (YTD), with the 12-month market performance down to -40.58% lower. It has a 12-month low price of $97.06 and touched a high of $173.25 over the same period. SRPT has an average intraday trading volume of 884.68K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -27.97%, -33.58%, and -41.48% respectively.
Institutional ownership of Sarepta Therapeutics Inc (NASDAQ: SRPT) shares accounts for 91.30% of the company’s 96.90M shares outstanding.
It has a market capitalization of $7.14B and a beta (3y monthly) value of 0.75. The stock’s trailing 12-month PE ratio is 30.85, while the earnings-per-share (ttm) stands at $2.38. The company has a PEG of 0.33 and a Quick Ratio of 3.18 with the debt-to-equity ratio at 0.88. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.52% over the week and 4.43% over the month.
Analysts forecast that Sarepta Therapeutics Inc (SRPT) will achieve an EPS of 1.38 for the current quarter, 2.65 for the next quarter and 15.58 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -2.99 while analysts give the company a high EPS estimate of -2.99. Comparatively, EPS for the current quarter was 0.73 a year ago. Earnings per share for the fiscal year are expected to increase by 408.03%, and 26.09% over the next financial year.
Looking at the support for the SRPT, a number of firms have released research notes about the stock. Deutsche Bank stated their Hold rating for the stock in a research note on February 11, 2025, with the firm’s price target at $136. Needham coverage for the Sarepta Therapeutics Inc (SRPT) stock in a research note released on November 27, 2024 offered a Buy rating with a price target of $202. H.C. Wainwright was of a view on November 25, 2024 that the stock is Sell, while Cantor Fitzgerald gave the stock Overweight rating on November 07, 2024, issuing a price target of $152- $167. Jefferies on their part issued Buy rating on October 21, 2024.
